Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) (PKD)
Status
Conditions
Details and patient eligibility
About
The primary objective of this study is to understand and characterize the health-related quality of life (HRQoL) and disease burden of adult participants with PK deficiency receiving routine clinical care. This study is an observational (i.e., noninterventional), longitudinal, multicenter, global registry for participants with PK deficiency, a rare nonspherocytic hemolytic anemia.
This study will be open for enrollment for 2 years and all enrolled participants will be followed prospectively for up to 96 weeks.
Data will be collected from participants who have provided informed consent and authorization pursuant to applicable laws and regulations.
Full description
Participants aged ≥18 years and previously enrolled in Study AG348-C-008 (NCT03481738) will be eligible to participate in this study. Data will be submitted via electronic patient-reported outcomes (ePRO) application.
All data collection efforts will abide by this protocol and be prospectively disclosed in the study informed consent. This study, with the appropriate participant (and or parent/guardian) consent/assent, may incorporate retrospective data from other properly consented studies done for the purpose of examining the longitudinal natural history of PK deficiency.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Participant must be greater than or equal to (≥)18 years of age;
- Participant must be enrolled in Study AG348-C-008.
Exclusion criteria
- Participant is enrolled in an Agios-sponsored clinical study involving treatment with a pyruvate kinase activator.
Trial design
15 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Agios Medical Affairs
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal